IL23A and psoriasis: Conversely, treatment with IL-23p19 antagonists achieves a relatively long-term response in psoriasis patients, which can be partly explained by these agents promoting trans-differentiation of Th17 cells into CD4+ Tregs by blocking the action of IL-231.